GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » PE Ratio

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) PE Ratio : 53.45 (As of Jun. 10, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-10), Shenzhenlubris Pharmaceuticals Co's share price is ¥27.26. Shenzhenlubris Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.51. Therefore, Shenzhenlubris Pharmaceuticals Co's PE Ratio for today is 53.45.

During the past 13 years, Shenzhenlubris Pharmaceuticals Co's highest PE Ratio was 647.67. The lowest was 14.31. And the median was 27.62.

Shenzhenlubris Pharmaceuticals Co's EPS (Diluted) for the three months ended in Mar. 2024 was ¥0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.51.

As of today (2024-06-10), Shenzhenlubris Pharmaceuticals Co's share price is ¥27.26. Shenzhenlubris Pharmaceuticals Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.55. Therefore, Shenzhenlubris Pharmaceuticals Co's PE Ratio without NRI ratio for today is 49.38.

During the past 13 years, Shenzhenlubris Pharmaceuticals Co's highest PE Ratio without NRI was 164.12. The lowest was 14.41. And the median was 27.41.

Shenzhenlubris Pharmaceuticals Co's EPS without NRI for the three months ended in Mar. 2024 was ¥0.18. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.55.

During the past 12 months, Shenzhenlubris Pharmaceuticals Co's average EPS without NRI Growth Rate was -6.30% per year. During the past 3 years, the average EPS without NRI Growth Rate was 389.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.70% per year. During the past 10 years, the average EPS without NRI Growth Rate was -18.20% per year.

During the past 13 years, Shenzhenlubris Pharmaceuticals Co's highest 3-Year average EPS without NRI Growth Rate was 389.80% per year. The lowest was -85.60% per year. And the median was 26.20% per year.

Shenzhenlubris Pharmaceuticals Co's EPS (Basic) for the three months ended in Mar. 2024 was ¥0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.51.

Back to Basics: PE Ratio


Shenzhenlubris Pharmaceuticals Co PE Ratio Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co PE Ratio Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.32 472.17 54.64 56.64 62.81

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.29 54.72 57.02 62.81 57.08

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's PE Ratio

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's PE Ratio falls into.



Shenzhenlubris Pharmaceuticals Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Shenzhenlubris Pharmaceuticals Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=27.26/0.510
=53.45

Shenzhenlubris Pharmaceuticals Co's Share Price of today is ¥27.26.
Shenzhenlubris Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.51.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Shenzhenlubris Pharmaceuticals Co PE Ratio Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines